echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > 1.5 billion tablets exported to the European Union

    1.5 billion tablets exported to the European Union

    • Last Update: 2017-08-23
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    [enterprise news of China Pharmaceutical network] on August 15, 2017, the interview team of "innovation and development of Shandong enterprises - gathering new energy of Shandong" came to Shandong Xinhua Pharmaceutical Co., Ltd (hereinafter referred to as "Xinhua Pharmaceutical") Zhang Daiming, Secretary of the Party committee and chairman of the company, showed the quality and strength of the pharmaceutical factory with "red gene" to reporters with a series of brilliant words Internet media reporters visit Xinhua Pharmaceutical "All the drugs in production of Xinhua Pharmaceutical have passed the new national GMP certification, 14 products have passed the FDA inspection, 9 products have obtained the EU cos certificate, the tablets have passed the MHRA audit of the UK drug and health products administration, the injection has passed the IDA audit of the International Pharmacy Association, and has been exported to the EU market for 1.5 billion tablets, becoming the first batch of 15 countries to implement the internationalization of preparations One of the strategic leading enterprises and one of the top ten national pharmaceutical export enterprises " Zhang Daiming said Xinhua Pharmaceutical Co., Ltd was founded in 1943 in Jiaodong Anti Japanese base and moved to Zibo in 1948 At present, it is a listed company of H-share and A-share, and it is the world's largest antipyretic and analgesic drug The production and export base is also an important manufacturer of anti infective, cardio cerebrovascular, central nervous, anti metabolism, digestive system, antibody and other drugs in China In the first half of this year, the company achieved an operating revenue of 2.45 billion yuan and a profit and tax of 330 million yuan In July, the company was listed on the brand image list of Shandong Province's kind Shandong merchants In Zibo, when people go on a business trip, they have to prepare the Pipemidic Acid and Ibuprofen Tablets of Xinhua Pharmaceutical Xinhua's antipyretic and analgesic drugs ibuprofen tablet and aifeile, the digestive system medicine Baochang, the new generation of gastrointestinal medicine Shutai De, the cardiovascular and cerebrovascular medicine Jiening, nimodipine tablet, diabetes medicine jiaheluo, dunling, anti infective medicine Pipemidic Acid tablet, xindaruo, are known as "Ten Golden Flowers" Quality is the core of Xinhua Pharmaceutical's social responsibility Good medicine cures, bad medicine kills For drugs, the quality is the most important The quality values of "product quality is related to the life of the enterprise, and drug quality is related to the life of people" have been thoroughly implemented by the whole staff and the whole process The company pays attention to quality investment, and has established the whole process quality control system from raw materials entering the factory, production links to products leaving the factory In the 1990s, Xinhua Pharmaceutical Group won the "quality management award" in China, and 23 products have won the product awards at the provincial and ministerial level, including 3 products won the national gold quality award, 3 products won the national silver quality award, and many products won the products of Shandong Province At present, all the drugs in production of Xinhua Pharmaceutical have passed the national GMP certification, 14 products have passed the FDA inspection, 9 products have obtained the EU cos certificate, the tablets have passed the MHRA audit of the UK drug and health products administration, the injection has passed the IDA audit of the International Pharmacy Association, and has been exported to the EU market for 1.5 billion tablets, becoming the first batch of 15 countries to implement the internationalization of preparations One of the strategic leading enterprises and top ten pharmaceutical export enterprises in China   In 2012, CCTV exposed the event of "poison capsule" In order to protect the rights and interests of enterprises whose primary responsibility is product quality, Shandong Provincial Drug Administration quickly released the announcement of "no repeat self inspection" capsule drug manufacturers in Shandong Province Because Xinhua Pharmaceutical has always selected raw materials and auxiliary materials of good quality, and each batch has been strictly inspected in accordance with national regulations, the product quality is impeccable , thus it is publicized as inspection free enterprise In recent years, due to the quality problems of many pharmaceutical enterprises' products, the export products have encountered the crisis of distrust in the international market The US FDA has repeatedly revoked the certification certificate of Chinese pharmaceutical enterprises and closed the market door for Chinese enterprises On March 31, 2016, FDA of the United States came to Xinhua Pharmaceutical to conduct on-site inspection on 14 products in three parks of the company for two weeks As a result, Xinhua Pharmaceutical passed with zero defects FDA inspectors have a high opinion on the effective operation of the company's quality system International Xinhua opens the door to more than 100 well-known multinational enterprises Xinhua Pharmaceutical supplies more than 30000 tons of APIs, more than 8 billion tablets, nearly 2 billion capsules and 1 billion injections to the world every year, with an export value of US $200 million It has more than 1 / 3 of the global market share of several leading products, such as aspirin and ibuprofen It has established long-term strategic cooperation with more than 100 well-known multinational enterprises, such as Bayer, brigor and, GlaxoSmithKline, etc Xinhua Pharmaceutical is rated as one of the top five enterprises of raw materials export of Western medicine in China, and Xinhua brand is listed as the export brand of key cultivation and development by the Ministry of Commerce and Shandong Province In 2003 and 2013, Xinhua Pharmaceutical also established European branch and American branch respectively In recent years, Xinhua Pharmaceutical has accelerated international cooperation in preparations Among them, the orders for cooperation with Bayer, such as Shenhe Sanlitong and bailigo Ibuprofen Tablets, have increased significantly; the newly introduced ibuprofen capsules and loperamide capsules, which have been cooperated with bailigo UK, have been formally delivered; the international cooperation agreement has been formally signed with the DSP cooperation project Zhang Daiming, chairman of Shandong Xinhua Pharmaceutical Co., Ltd., introduced that the first phase of the project of modern pharmaceutical international cooperation center with an investment of 800 million yuan is about to be completed, and various preparations are being put into production After three to five years' efforts, the production of solid preparations has increased from 8 billion to 20 billion, of which about 50% are exported to European and American markets In the future, Xinhua Pharmaceutical is not only a well-known API manufacturer, but also a global pharmaceutical manufacturer Science and technology Xinhua, with more than 100 new products Xinhua Pharmaceutical is a national high-tech enterprise, a key high-tech enterprise of the national torch plan, and a backbone enterprise of the national Torch Plan biomedical industry base It has an enterprise technology center, and six talent platforms, including academician workstation, postdoctoral workstation, Taishan industrial talent post, Taishan academic post, master's joint training point, and Shandong technician workstation On the basis of consolidating the traditional advantages, the company has focused on eight categories of drugs, including cardio cerebrovascular, digestive system, anti-tumor, anti metabolism, central nervous system, anti infection and antibody, increased R & D investment, and distributed more than 100 new products At present, it has 401 drug production numbers, including 8 national first class new drug numbers, 21 second class new drug numbers and 241 authorized ones   In recent years, Xinhua Pharmaceutical has strengthened the cooperation between universities and enterprises, established a comprehensive strategic cooperation relationship with Shenyang Pharmaceutical University, established a postdoctoral research workstation, University practical education base, and research incubator for young teachers; cooperated with Tsinghua University School of pharmacy to build a platform for "consistency evaluation of solid dispersion system of insoluble drugs"; established jointly with Qingdao University of science and technology "Advanced Manufacturing Engineering Technology Center for antipyretics and analgesics" was established, and a strategic cooperation agreement was signed; cooperation with Shandong University of science and technology is applying to Shandong Provincial Key Laboratory for Joint Master Training in Xinhua to promote research and development of innovative drugs The company attaches great importance to scientific research investment, with annual R & D investment of more than 100 million yuan From January to June this year, the company invested 96.51 million yuan in scientific and technological innovation, which has reached the level of last year At the same time, it attaches great importance to the construction of R & D talent team, forming a talent team composed of 11 doctors, more than 260 masters and more than 800 undergraduates At present, there are 7 technicians in Shandong Province, 10 technicians in Zibo City, 567 technicians and 787 technicians in terms of high skilled talents, which account for more than 35% of the total number of skilled workers Three researchers have been awarded the first batch of industrial leading talents by Shandong Provincial People's government Among the foreign experts introduced, two won the Zibo Friendship Award and one won the Qilu Friendship Award The responsibility of Xinhua is the crystallization of red culture It is understood that Xinhua Pharmaceutical is 6 years older than the Republic of China and is a worthy meritorious pharmaceutical factory Social responsibility is the connotation of "Xinhua brand" responsibility culture construction Xinhua Pharmaceutical has gone through the whole process of the founding, construction and development of the Republic of China, such as the Anti Japanese War, the liberation war, the construction of new China, the reform and opening up, and created many "" in the history of Chinese pharmaceutical industry, which has made indelible contributions to the development of the national pharmaceutical industry and the life and health of the people Xinhua Pharmaceutical takes "protecting health and benefiting the society" as its corporate mission, and strives to fulfill its social responsibilities in terms of saving lives, curing diseases and saving people, product quality, energy conservation and emission reduction, employee development, environmental protection and other aspects, with remarkable achievements The company invests more than 20 million yuan every year to implement safety transformation and improve the labor environment It invests 100 million yuan every year to do a good job in environmental protection, to ensure the discharge up to the standard It implements more than 100 safety and environmental protection technology improvements every year It has been praised by the local government for many times, and has been rated as the advanced safety enterprise and energy conservation and emission reduction enterprise in Shandong Province Over the years, Xinhua Pharmaceutical has completed its tax payment obligations on time in strict accordance with national laws and regulations, and has been rated as a class a tax payment enterprise by the tax authorities In 2016, the company realized profits and taxes of 484 million yuan, of which 358 million yuan was paid in taxes For many years in a row, the tax revenue ranks among the enterprises in Zibo High tech Zone Xinhua takes the performance of social responsibility as its own duty and actively performs its moral responsibility When the country is in great disaster, we should actively donate money and materials For the "5.12" Wenchuan earthquake, "4.28" Jiaoji railway accident, Qinghai Yushu earthquake, Sichuan Ya'an earthquake, donation reached 5 million yuan In the past three years, Xinhua Pharmaceutical has donated more than 1 million yuan to the municipal Charity Association, Red Cross Society and other social organizations Over the years, Xinhua Pharmaceutical has insisted on actively participating in social assistance, loving the public welfare, giving love and fulfilling the social responsibility of the enterprise The company has been awarded the honorary titles of "contribution award of social responsibility of Chinese pharmaceutical enterprises", "national support for public welfare undertakings, enterprise dedicated to people's health", Shandong Province advanced unit of free blood donation, Zibo Charity Award caring enterprise, etc   As a well-known brand in the domestic pharmaceutical industry, Zhang Daiming, Secretary of the CPC Committee and chairman of the board of directors of Xinhua Pharmaceutical, said that in the future, efforts will continue to be made to strengthen brand building, take advantage of the favorable opportunity of being elected as a brand enterprise of "benevolent Lushang", further enhance the brand image of Xinhua, promote the development of enterprises with brand building, and make efforts for the development of the pharmaceutical industry and the health of the people New and greater contributions.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.